Nomad Power Solutions Inc (LIXT)
NGM · Industrials · Electrical Equipment & Parts
Closing price as of 2026-09-02 · Source: TEK2day Finance
Key Metrics
About Nomad Power Solutions Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (775K) | (1.8M) | (1.8M) | (2.0M) |
| Net Income | (776K) | (2.0M) | (2.5M) | (1.9M) |
| Diluted EPS | $-0.29 | $-0.33 | N/A | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (6.3M) | (5.1M) | (3.6M) | (5.1M) |
| Net Income | (6.3M) | (5.1M) | (3.6M) | (6.0M) |
| Diluted EPS | $-3.99 | $-2.66 | $-1.59 | $-1.26 |